Eli Lilly (LLY) Notes Payables (2009 - 2014)

Eli Lilly has reported Notes Payables for 6 years, with the latest figure at $1.0 billion in Q1 2014.

• For the quarter ending Q1 2014, Notes Payables fell 2.72% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2014 stood at $1.0 billion (down 2.72% YoY), and the FY2013 full-year result was $1.0 billion, up 8409.24% from the prior year.
• Notes Payables for Q1 2014 stood at $1.0 billion, down from $1.0 billion in the prior quarter.
• The five-year high for Notes Payables was $1.6 billion in Q3 2011, with the low at $9.1 million in Q2 2012.
• Historically, Notes Payables has averaged $667.6 million across 5 years, with a median of $578.0 million in 2010.
• Annual changes were most pronounced in 2012 — Notes Payables plunged 99.44% — and 2013, when it soared 11143.96%.
• Eli Lilly's Notes Payables stood at $156.0 million in 2010, then soared by 875.83% to $1.5 billion in 2011, then sank by 99.22% to $11.9 million in 2012, then soared by 8409.24% to $1.0 billion in 2013, then declined by 1.24% to $1.0 billion in 2014.
• The last three Notes Payables figures came in at $1.0 billion (Q1 2014), $1.0 billion (Q4 2013), and $1.0 billion (Q2 2013), per Business Quant data.